Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins
Name
developing-a-sars-co-v-2-antigen-test-using-engineered-affinity-proteins.pdf
Description
Accepted version
Size
4.99 MB
Format
Adobe PDF
Checksum (MD5)
1ba33dd4696507213a31301f624d7601
Author(s)
Kim, Seunghyeon
Yee, Emma
Miller, Eric A
Hao, Yining
Tay, Dousabel MY
Sung, Ki-Joo
Jia, Huan
Johnson, Joseph M
Saeed, Mohsan
Mace, Charles R
Date Issued
August 11, 2021
Journal
ACS Applied Materials & Interfaces
Publisher
American Chemical Society
Citation
Kim, Seunghyeon, Yee, Emma, Miller, Eric A, Hao, Yining, Tay, Dousabel MY et al. 2021. "Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins." ACS Applied Materials & Interfaces, 13 (33).
Version
Author's final manuscript
Abstract
The ongoing COVID-19 pandemic has clearly established how vital rapid, widely accessible diagnostic tests are in controlling infectious diseases and how difficult and slow it is to scale existing technologies. Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks. The pair with the highest biomarker sensitivity was then integrated into a 10 min, vertical-flow cellulose paper test. Notably, the as-identified affinity proteins were compatible with a roll-to-roll printing process for large-scale manufacturing of tests. The test achieved 40 and 80 pM limits of detection in 1× phosphate-buffered saline (mock swab) and saliva matrices spiked with cell-culture-generated SARS-CoV-2 viruses and is also capable of detection of N-protein from characterized clinical swab samples. Hence, this work paves the way toward the mass production of cellulose paper-based assays which can address the shortages faced due to dependence on nitrocellulose and current manufacturing techniques. Further, the results reported herein indicate the promise of RAPIDS and engineered binder proteins for the timely and flexible development of clinically relevant diagnostic tests in response to emerging infectious diseases.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution-Noncommercial-ShareAlike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1021/acsami.1c08174
